A working comparison of the disease surveillance platforms people actually evaluate — BlueDot, Airfinity, GIDEON, ProMED-mail, Virus Watcher and ENCLAI — alongside the free public sources most buyers should try first. Competitor facts were taken from each vendor’s own public site on ; anything we could not confirm there is marked unverified rather than asserted.
There isn’t one. “Best” depends on which of nine jobs you are doing, and the nine jobs are served by different tools. In eight of them the answer below is not ENCLAI. If you want a HealthMap alternative you are usually after informal-signal detection; if you want a ProMED alternative you are usually after expert narrative. Both are different products from a normalised case-count database, and buying the wrong one is the common failure in this category.
| Your job | Start with | In short |
|---|---|---|
| Spot an informal signal early | HealthMap (free), BlueDot (paid) | ENCLAI has no informal-signal lane at all |
| Expert judgement on one unfolding event | ProMED-mail, CIDRAP, WHO DON | ENCLAI adds no commentary |
| Something to read daily | CIDRAP | Free daily news and analysis, university-run |
| Official numbers for one agency’s geography | That agency — US CDC, ECDC | Free at source; do not pay anyone for it |
| A forecast, risk score or projection | Airfinity, BlueDot | ENCLAI never forecasts, by design |
| Clinical reference, differential diagnosis | GIDEON | ENCLAI is not a clinical tool |
| Individual-level case records | Global.health | ENCLAI holds aggregates only |
| Long-run comparable indicators and charts | Our World in Data | Free, chart-level CC BY, built for trends |
| Case counts compared across many countries and diseases | ENCLAI | The one job we built for — and it is priced openly |
Inclusion policy, stated openly so you can judge the omissions: a tool is here if a buyer looking for outbreak data would plausibly put it on a shortlist against ENCLAI, or if it is a source that a buyer should try before paying anyone. Nobody paid to appear. Four groups, and the distinction matters more than any ranking:
Virus Watcher is here for a specific reason: it ranks for the same consumer searches as this page, not because a procurement team would shortlist it against a B2B data subscription. Considered and not included: Ginkgo Biosecurity/Metabiota, EpiWATCH and the travel-risk intelligence suites. We did not fetch and verify their public pages on 29 July 2026, and under this page’s own rule we will not write about a vendor we did not check. Their absence is a limit of our research, not a judgement about them.
We have deliberately not scored the free and academic resources against ENCLAI on price or “value for money”. Ranking a university research centre against a subscription product on value produces a number that means nothing. What each one is for is the useful question, and every resource named above gets an answer below — in the routing table, in Free and academic sources, or both.
The detail layer for the quick answer above. In eight of the nine rows, the recommendation is not ENCLAI.
| If your job is… | Start with | Why |
|---|---|---|
| Seeing an informal signal early — news, local-language media, an event that has not reached an official bulletin yet | HealthMap, or BlueDot if you can buy | Free, and we do not compete here. HealthMap — run by Boston Children’s Hospital with Harvard Medical School, per the site’s own footer on 29 July 2026 — harvests news wires, expert reports and official postings in multiple languages, geocodes them and links alerts back to the originating item. Free to browse with no account; an account is needed for email alerts. HealthMap’s about page returned HTTP 404 for us that day, so we do not restate its founding year or its source-language count. BlueDot sells work in the same class commercially with a 24/7 analyst team; we cannot compare the two on scale from outside and do not try. ENCLAI ingests authority-published data only and has no informal-signal lane, so it cannot help you here. |
| Expert narrative and judgement about one unfolding event | ProMED-mail, CIDRAP, or the WHO DON | Judgement is the product, and it is not ours. ProMED-mail, from the International Society for Infectious Diseases, publishes human-moderated outbreak reports; the site describes itself as holding “31 years of outbreak data”. CIDRAP — the Center for Infectious Disease Research and Policy, in the University of Minnesota’s Research and Innovation Office — publishes free daily infectious-disease news and analysis. A WHO Disease Outbreak News item is WHO’s public report on a confirmed or potential acute public health event — in WHO’s words it “provide[s] information on confirmed and potential acute public health events of concern across all hazards” — usually with WHO’s own risk assessment attached. ENCLAI adds no commentary, so none of this is something we offer. |
| Keeping up daily with what is happening and what experts make of it | CIDRAP | Free, daily, and better than us at this. News and analysis from the Center for Infectious Disease Research and Policy at the University of Minnesota, alongside its policy research programmes. If you want one thing to read every morning, it is this, and it costs nothing. ENCLAI does not interpret and is not a substitute. |
| Official figures for a single agency’s own geography | That agency, directly | Do not pay anyone, including us, for a number one agency publishes for free.
For the United States, US CDC’s NNDSS and FluView are free and available in bulk via
the open API on data.cdc.gov — a query such as
https://data.cdc.gov/resource/x9gk-5huc.json returned JSON to us unauthenticated
on 29 July 2026, with no purchase and no account. An application token is optional but
sensible for bulk pulls: Socrata, which hosts the platform, states that untokened requests
come “from a shared pool via IP address” and can be throttled, while tokened
requests are not. Condition and jurisdiction counts change between annual NNDSS tables, so
read the current figures off the dataset page rather than off us. For the EU/EEA, the ECDC
Surveillance Atlas gives free query output with harmonised TESSy case definitions. |
| A forecast, a risk score, or a projection you can defend in a committee | Airfinity or BlueDot | ENCLAI is the wrong tool at any price. Airfinity sells respiratory forecasting, demand and scenario modelling and named analyst support; BlueDot sells outbreak-suitability and population-vulnerability modelling plus expert-written rapid risk assessments. ENCLAI has no forecasting, no modelling and no analyst layer, by design and permanently. |
| Clinical differential diagnosis, treatment guidance, pathogen identification, or deep historical epidemiology | GIDEON | A different category of product. GIDEON is a clinical and research reference work; it states coverage of 370+ infectious diseases, 100,000+ prevalence and seroprevalence surveys, phenotypic identification across 2,000+ bacteria, and differential-diagnosis tooling. Those are GIDEON’s own figures, not measurements of ours. ENCLAI does none of it. |
| Individual-level case records for modelling | Global.health | An aggregate cannot substitute for a line list. Global.health publishes anonymised line lists with per-case source attribution, from a consortium including Boston Children’s Hospital, Harvard Medical School, Northeastern, Oxford, Georgetown and Johns Hopkins. Access is via the site and a public API; check their Terms of Use for reuse conditions — we did not verify the licence text on 29 July 2026 and do not restate it. All ENCLAI records are aggregate counts. |
| Long-run comparable indicators, charts and downloadable series for context rather than live outbreak counts | Our World in Data | Free, and built for a different timescale. Published by the Global Change Data Lab, a UK non-profit. Its own charts and writing are CC BY, with the source and its licence stated on every chart. It exists to explain trends over years, not to track an event this week — a different job from ours, and it is better than ours at it. |
| Comparing case counts across many countries and diseases in one place, with a credibility grade and a source record behind every figure | ENCLAI | This is the one job we built for. 444 active feeds normalised into one view across 235 countries and territories and 217 diseases and pathogens, on one live map. 1,147,416 records, every one carrying an internal source record — though only the ~23.9% originating from publicly named bodies can be traced by you without a contract (see what you can and cannot verify). A published credibility grade on every record, and a published price. If you only need one country or one agency, go to that agency instead. |
Six disease surveillance platforms a buyer would realistically shortlist. Every claim below is either taken from the vendor’s own public pages as fetched on 29 July 2026, or marked unverified. Where a vendor publishes a figure about itself that we cannot check from outside, it is attributed to them rather than stated as fact.
| Platform | Price published? | What it primarily sells | Reuse licence |
|---|---|---|---|
| ENCLAI | Yes — Pro is $49/month, listed publicly | Normalised, source-linked case counts across 235 countries and territories and 217 diseases | CC BY-NC-SA 4.0 on our layer of the free public surface — the published figures, not the source catalogue or the paid live feed; commercial use licensed separately |
| BlueDot | No — quote-only; bluedot.global/pricing/ returned HTTP 404 | Early warning from multilingual media and official sources, 24/7 analyst team, rapid risk assessments, forecasting | None published; we could not locate a terms-of-use page. Assume contractual |
| Airfinity | No — quote-only; airfinity.com/pricing returned HTTP 404 | Predictive analytics for pharma and government: respiratory forecasting, demand modelling, biorisk intelligence, analyst support | None published; only Cookies and Privacy Policy links were reachable |
| GIDEON | No — a pricing page exists at gideononline.com/plans/ and returns HTTP 200, but it states no figure and directs you to book a demo. Corrected 2 September 2026: this cell previously said the pricing URLs returned HTTP 404, which was wrong. | Curated clinical and epidemiological reference: outbreak history, prevalence surveys, differential diagnosis, treatment, microbiology | Proprietary and restrictive per the licence terms we could reach |
| ProMED-mail | Yes — $0 Freemium, $10/month Standard, $1,000/year Pro; commercial, government and academic tiers custom-priced | Human-moderated narrative outbreak reports, by email and on the web | Proprietary; we could not retrieve the full terms text — read it before reusing |
| Virus Watcher | No — free tier usable without an account; a “Premium Service” and an enterprise tier exist with no price attached | A consumer outbreak-tracking app: global map, country and disease rankings, travel view, news feed, an “Ask AI” layer | Personal, non-commercial informational use only; commercial redistribution requires written authorisation |
If you arrived looking for a HealthMap alternative, you are almost certainly after informal-signal detection — media reports, clinician chatter and local-language items ahead of an official bulletin. ENCLAI is not an alternative to HealthMap and we will not pitch it as one. The realistic options are: HealthMap itself (free, browsable without an account); ProMED-mail, whose Freemium tier is $0 and which reaches informal reports through its moderator network; and BlueDot if you have a budget and want the same class of work commercially with analyst support. For public-health institutions, WHO EIOS covers this ground, but access runs through institutional channels rather than a sign-up page. Outbreaks Near Me is often suggested here; both URLs we tried returned no content on 29 July 2026, so we cannot confirm it is still collecting reports — check before relying on it.
People searching for a ProMED alternative usually want one of two different things. If you want the narrative — an expert telling you what an event means — the substitutes are CIDRAP (free, daily, University of Minnesota) and WHO Disease Outbreak News (free, with WHO’s own risk assessment), or a commercial analyst desk at BlueDot or Airfinity. If you want the numbers in a form you can join, sort and chart, that is a different object: ProMED posts are prose with figures inside them, and ENCLAI is a normalised case-count database with a source record per figure. One is not an upgrade of the other. ProMED Standard is also one fifth of our price.
Two of the rows below are scope decisions we will not reverse. The rest are places where a rival is simply better and we have no roadmap that closes the gap.
| Axis | Who wins | The honest position |
|---|---|---|
| Forecasting and interpretation | Commercial: Airfinity, BlueDot · Non-commercial: CIDRAP, ProMED, WHO | ENCLAI produces no forecast, no risk score and no expert commentary, and does not plan to. If you need a projection you can defend in a committee, that is a commercial purchase — Airfinity and BlueDot sell it. If you need expert judgement on a specific event, CIDRAP and ProMED publish it and WHO attaches its own risk assessment to a Disease Outbreak News item; those are not products for sale and we are not implying they are. We are not a substitute for either kind. |
| Analyst support — a human who answers your question | BlueDot, Airfinity, GIDEON | All three sell access to people. ENCLAI has no analyst layer, no research desk and no named analyst attached to an account. If your question is “what does this mean for our programme in Q4”, we cannot answer it and they can. |
| Independent evaluation of method | Not established for rivals — but certainly not ENCLAI | We did not audit any vendor’s publication or accreditation record this run, so we assert nothing about theirs. What we can state is our side: ENCLAI’s normalisation and credibility grading have never been peer-reviewed or externally audited, and every ENCLAI number on this page is self-measured. If external validation of method is a requirement, nothing here should reassure you about us. |
| Openness of the free tier | US CDC, ECDC, Our World in Data, HealthMap, Global.health | ENCLAI public pages show only the top 10 rows of each case-count table; full per-country and per-disease figures and the API sit behind Pro at $49/month. US CDC gives you NNDSS free through an open API with no purchase or account. Our World in Data and the ECDC Atlas impose no comparable row cap. On “how much can I get for nothing”, we lose outright. |
| Licence permissiveness | US CDC, ECDC, Our World in Data | US federal works are generally public domain, with two caveats CDC itself makes: third-party material on CDC pages may still be copyrighted, and CDC asks that its name and logo not be used in any way implying endorsement (we use neither, and CDC has not endorsed us). ECDC website and database content is CC BY 4.0. Our World in Data licenses its own charts and writing CC BY, while being explicit that most underlying data comes from third-party providers under those providers’ terms. ENCLAI’s free surface is CC BY-NC-SA 4.0 and commercial use must be licensed separately. If you want to build a commercial product on the data, their terms are more open than ours. |
| US depth and granularity | US CDC | NNDSS covers notifiable conditions across every US jurisdiction weekly, and FluView adds age, HHS region and provider denominators. Nobody normalising global feeds matches that resolution inside the United States. If your scope is the US, use NNDSS and FluView directly and do not pay us. |
| Cross-country comparability within Europe | ECDC | TESSy applies harmonised EU case definitions, so a case in Portugal means the same thing as a case in Finland. Normalising 444 heterogeneous feeds cannot fully replicate that and we should not imply it does. The trade-off is specific to the validated annual datasets, not to ECDC as a whole: on the single Surveillance Atlas disease page we opened on 29 July 2026, the most recent reporting year available was roughly two to three years back. One page is not a characterisation of ECDC’s cadence, and ECDC publishes far faster elsewhere — its weekly Communicable Disease Threats Report and weekly respiratory bulletins are current. |
| Informal and pre-official signal | HealthMap, BlueDot, ProMED (and, for institutions with access, WHO EIOS) | ENCLAI is structurally downstream of official publication. Media reports, clinician submissions, local-language rumour, wastewater, mobility and self-reported symptoms are all signal classes we do not collect. We will never claim to see an outbreak before the authorities do, because we cannot. |
| Institutional standing and archive depth | ProMED, HealthMap, CIDRAP, GIDEON, WHO, BlueDot | ProMED describes itself as holding 31 years of outbreak data; HealthMap has run for many years at Boston Children’s Hospital with Harvard Medical School; CIDRAP sits inside a university; WHO’s Disease Outbreak News archive runs back to the early 1990s (the earliest year exposed by the archive filter when we checked on 29 July 2026 was 1990). ENCLAI is a young, small Virginia LLC with no comparable publication record, and this page does not state an earliest-record date for our corpus because we have not published one. That is a real reason to prefer them for a citation. |
| Continuity risk | Effectively every other organisation here | ProMED sits inside a non-profit society, HealthMap inside a children’s hospital and a medical school, CIDRAP inside a university, NNDSS and TESSy inside government. Enclai LLC is a small Virginia company. If your workflow must still work in five years, that is a genuine argument against depending on us. |
| Freshness you can audit | Unresolved — nobody on this page wins it cleanly | We note a rival’s stale “26 days ago” label above, so we owe you the symmetric disclosure: the byline date at the top of this page is the last build of the public site, not the age of the underlying figures. Feed cadences differ — some authorities publish weekly, some monthly, some irregularly — and we do not currently publish a median record age or a per-feed cadence table. Until we do, you cannot audit ENCLAI freshness from the outside, and you should not assume it. |
| Cheapest paid entry point | ProMED-mail | ProMED Standard is $10/month with email delivery, from a non-profit — verified on their subscribe page on 29 July 2026 ($0 Freemium, $10/month Standard, $1,000/year Pro, custom commercial, government and academic tiers). Different product. One fifth of our price. |
Stated plainly, so nobody buys the wrong thing:
Traceability is the axis we compete on, so test it hardest — on us first. Figures originating from the 53 named bodies you can trace to a bulletin yourself. The other 76.1% you cannot, without a contract. Both are true at once, and we would rather you learn the second one here than discover it in a review.
Free public surface: CC BY-NC-SA 4.0 — on our layer only, and it is a truncated surface. The licence covers ENCLAI’s normalisation, structuring and presentation. It does not and cannot restrict the underlying authority data, which stays under whatever terms its publisher set: US federal works are generally public domain, ECDC website and database content is CC BY 4.0, WHO material is under WHO’s own terms. If you want the source data on the source’s terms, take it from the source — we are not a licensing chokepoint on public data and do not claim to be.
Researchers, healthcare professionals, hospitals, public-health agencies and NGOs may use and cite our layer free, today, with no contract. Attribution must credit ENCLAI and the originating health authority, and must state that the figures were normalised by us rather than published by them in that form. Where the authority prescribes its own credit line, use theirs — ECDC, for example, requires acknowledgement of ECDC as creator, a link to the CC BY 4.0 licence, an indication that the material was modified, and for database content the credit “Dataset provided by ECDC based on data provided by public health authorities, scientific institutes or health care providers in the relevant reporting countries and/or by WHO.” Share-alike applies to derivatives of our layer. Commercial use of our layer is licensed separately; ask at /contact.
What is capped. What is free is the top 10 rows of each case-count table, not the full dataset. Complete per-country and per-disease figures and the API are part of ENCLAI Pro at $49/month. What that $49 includes in detail — seats, rate limits, historical depth, redistribution rights, support — is on the pricing page and we are not restating it here, so read it before assuming. If you need complete figures for a paper, write to us; we would rather license it than have you cite a truncated table. Dataset scope and terms are at the dataset page.
How competitor facts were gathered. On we fetched each vendor’s public website and, where a product was usable without login, the product itself. Prices, licence terms, coverage claims and calls to action are quoted from those pages. Where a page returned HTTP 404 or was login-gated, that is stated in the relevant cell rather than filled in by inference. We did not contact any vendor’s sales team, so we hold no non-public pricing for any quote-only product and publish no estimate of one. Vendor self-reported metrics we could not check — reach figures, lead-time claims, coverage counts — are attributed to the vendor and marked unverified rather than repeated as fact.
Two dates, and they are not the same. Competitor facts were verified on and are not re-checked when this page rebuilds. The “data last updated” timestamp in the byline is the last build of the ENCLAI public site, which runs far more often, and it is not a statement about the age of any competitor fact or of any individual surveillance record.
ENCLAI figures, and the asymmetry in them. Every competitor fact here comes from a page anyone can open. Every ENCLAI figure here was measured by us, against our own database, on 29 July 2026, with no external audit — you cannot check 1,147,416, 444 or 93.6% the way you can check ProMED’s $10. Hold our numbers to a lower standard of proof than the ones we quote about other people: they have had less scrutiny. The structural counts on this page (444 feeds, 235 countries, 217 diseases, 53 named bodies) render live from the same source directory that builds /sources, so they cannot drift away from it. The record-level figures — the source mix and the credibility mix — are still fixed text measured on 29 July 2026 and will be wired to the live query next.
Independence. ENCLAI is operated by Enclai LLC, Virginia, USA. It is not affiliated with, endorsed by, or accredited by the World Health Organization, ECDC, the US Centers for Disease Control and Prevention, or any national health agency. Nothing here is an endorsement by, or an affiliation with, any named vendor or organisation, and no vendor reviewed this page before publication. All trademarks are the property of their owners.
Corrections. If any statement about your organisation is inaccurate or out of date, write to us. We will verify against your live site, correct the page, and note the correction and its date. Our policy is at /editorial-policy#corrections.
Scope. ENCLAI is decision-support for disease surveillance. It is not a substitute for official public-health surveillance, not medical, regulatory or clinical advice, not a medical device, and not FDA-approved. Editorial oversight: Dr Natalya Mathur. Methodology: /trust/methodology.
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.
